Serum soluble LIGHT in the early third trimester as a novel biomarker for predicting late-onset preeclampsia

Abstract Our aim was to evaluate whether serum levels of soluble LIGHT (sLIGHT) at 27–31 weeks can predict the later occurrence of gestational hypertension (GH), late-onset preeclampsia (PE), and early-onset PE. Mean blood pressure (MBP), soluble fma-like tyrosine kinase 1/placental growth factor (sFlt-1/PlGF) ratio at 27–31 weeks, and sLIGHT at 27–31 weeks were independent risk factors for late-onset PE. The combination of the three risk factors improved sensitivity with a false-positive rate of 10% (MBP: 60%, log 10 (sFlt-1/PlGF): 45%, sLIGHT: 35%, combination: 75%). Serum sLIGHT in the early third trimester may be a novel biomarker for predicting late-onset PE.